AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2012
Mar 5, 2012
31868_dirs_2012-03-05_0eb0b436-b337-4658-a388-0d2d8e7628c0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2012-03-01
Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-03-01 | Common Stock | A | 5600 | — | Acquired | 30600 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-03-01 | Emp. Stock Option (Right to Buy) | $4.73 | A | 31000 | Acquired | 2022-03-01 | Common Stock (31000) | Direct |
Footnotes
F1: Restricted Stock Award-25% vest per year
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20